The Smart Labs Module is part of the state-of-the-art Hataali blockchain platform, which is interoperable with MES’ as well as other lab software system. Reef Group’s GMP-compliant manufacturing facilities for cell and gene will get a significant boost in terms of digitisation.

Synergies from this collaboration include full visibility into lab inventory and processes, with therapy developers empowered with full digital monitoring, automated procurement and transparency of all items within the lab. This provides the ability to use Hataali's patented blockchain layer for inventory management as well as procurement.

Significantly, the partnership also opens-up new areas and solutions with Hataali’s Smart Lab module offering real-time monitoring of some of the largest cell and gene therapy labs. Further advantages include the ability to use future-proof technologies such as smart contracts for the procurement process.

Piers Slater, CEO at Reef Group said, “We are pleased to be working with Hataali, the only award winning ATMP solution platform. We are impressed with the breadth of data solutions that they cover, not just for cell and gene therapy ordering and tracking, but the wider solutions for ATMP therapy providers. Partnering with Hataali means that we can not only provide state of the art, regulatory compliant facilities, but we can also provide full data infrastructure required by our clients ensuring that they can be operational within weeks of moving in. We believe that our relationship will mature to provide additional value add services to our clients in the future most importantly digital services around carbon footprint monitoring.”

With its expansion into lab digitisation and automation, Hataali is now the only holistic solution available for the cell and gene therapy sector.

Raja Sharif, CEO at Hataali, commented: “We are really excited to work with the Reef Group. This is a first-of-its-kind partnership to bring complete transparency to the journey of a single cell – from the donor to the vein of a recipient, but including all data on conditions of sample preparation and manufacture.

Hataali remains committed to supporting researchers and clinicians around the world in their efforts of getting these advanced therapies to the patients faster. Securing vital information through the full journey of these personalised medicines.”